responsible business supplement success depends ability research develop innovative products make accessible people responsible waygsk responsible business supplement supplement learn embed responsible business practice within business report key information approach responsible business alongside financial performance within annual report supplementary document provides additional context details progress responsible business commitments cover image nadeen debbie lindsay weybridge lab uk worked reformulation chlorhexidine solution used corsodyl mouthwash antiseptic gel could used help prevent umbilical cord infections developing countries guide using report guide navigation buttons dynamic links full screen mode interactive pdf designed help click dynamic links access pdf set view full screen mode easily navigate report find go main contents relevant information within report online exit full screen mode press escape view information looking use tabs top full toolbar search pdf navigate sections printerfriendly pdf use print icon navigation print print whole part document printfriendly format go preceding go next return last visitedgsk responsible business supplement contents inside report approach health behaviour people planet data summary learn ensure find read learn create find managing read key data business operates developing innovative products embedding values inspiring supportive work environmental impacts responsibly improving access throughout business environment encourages operations products healthcare patients around including ways employees develop across life cycle reduce world research develop sell capabilities achieve carbon emissions water use market products best waste chairmans statement approach approach approach approach data summary ceos statement innovation unmet ethical conduct developing people understanding summary medical needs inspiring healthy value chain carbon footprint assurance statement performance highlights promoting values sales workplaces better access medicines marketing practices aiming carbon neutral responsible business vaccines promoting inclusion practice transparency reducing water impact diversity building products better clinical trial data progress commitments reducing waste meet needs community volunteering rigorous patient create change reducing child mortality consumer safety strengthening healthcare minimising animal testing infrastructure promoting human rights eliminating controlling ensuring ethical interactions neglected tropical diseases approach tax fighting malaria working third parties eradicating polio access antiretroviral treatment hiv gsk responsible business supplement chairmans statement operating responsibly fundamental gsks strong performance responsible groups strategy since becoming chairman business evident companys high external benchmarking witnessed significant strides rankings external benchmarking exercises gsk making promoting innovation improving gsk topped access medicine index gsk topped access access healthcare challenging industry since inception maintained position medicine index norms issues sales practices dow jones sustainability index fourth consecutive time longstanding member ftsegood since biennial assessment board aims reinforce support began managements commitment operating ethically companys efforts reduce environmental responsibly worldwide board impacts also recognised corporate responsibility committee crc score carbon disclosure included dow oversee policies programmes across cdp reflecting extensive reporting gsk jones sustainability world business ensure company taking manages risks opportunities associated index score action interests society climate change approach managing economic environmental shareholders may nonexecutive water impacts also acknowledged social performance director lynn elsenhans took chair b score cdp water index crc following sir christopher gents improved score information groups responsible retirement board b secure business approach performance detailed place cdps ftse amongst several topics issues annual report responsible business climate disclosure crc reviewed companys commitment supplement provides detail leadership index operating transparently integrity material social environmental topics eighth consecutive year transformation commercial sets progress made towards recognition quality model also explored critical issue commitments disclosure climate balance need return investment continue welcome dialogue change impacts innovation need price products companys stakeholders matters related appropriately improve access patients supplement gsk continues pharmaceutical company hold carbon trusts yd eu ac r ng yw ea rer carbon standard cutting carbon emissions water standard reducing water use across philip hampton operations globally chairman member ftsegood since gsk responsible business supplement ceos statement whilst year substantial also increased attention whilst absolute carbon footprint change gsk remained fully price medicines notably usa increased year reduced focussed progressing responsible seek price medicines vaccines value chain carbon footprint products business commitments whether responsibly sustainably reflect shipped average compared proactive measures new ways value deliver patients healthcare also reduced direct carbon working healthcare professionals systems wider society customers emissions since extend responding societys ability pay tiered pricing approach access products particularly propellant pressing health needs like ebola vaccines commitment price medicines based inhalers reducing environmental least developed countries less impact across value chain increasingly gsks malaria candidate vaccine product european prices strong examples challenging continue look ways years research received positive approach developed markets continue minimise impact scientific opinion european regulators seek flexible approaches pricing look year use prevention malaria young given significant level restructuring within opportunities price according value children subsaharan africa group sought provide support usa six recently launched important step towards making vaccine leaving company invested medicines priced parity discount available alongside tools protect listening employees global staff survey medicines aim supercede children malaria provide participation rate year scored vaccine notforprofit price ensure january completed roll well measures empowerment resilience price barrier access new compensation model sales teams however scores employee engagement january stopped paying doctors understandably fell senior leaders across partnership save children achieved speak behalf instead engaging group already taking steps address major milestone submitted approval digital channels providing direct antiseptic gel prevent potentially fatal conclusion would like thank contact medical teams umbilical cord infections newborns developing employees partners continued hard changes step high expectations countries also accelerated development work supporting goals responsible society healthcare companies also candidate vaccine ebola response business efforts support improving performance outbreak west africa provided able achieve much year humanitarian support regions affected clear expectations ethical conduct people strengthened saw increased focus antibiotic resistance code conduct training increasing relevance spite scientific challenges area different cultures maintaining global gsk active pipeline includes standards remain vigilant aware potential new firstinclass treatment complex risk factors many markets moving towards phase iii development operate fulfilled commitment taking collaborative approach research sir andrew witty want work governments create clinical trial transparency three years since chief executive officer inception clinical trials database lists new economic models help secure trials research teams new supply antibiotics future given access detailed trial datagsk responsible business supplement approach performance highlights global healthcare company biggest contribution make society fighting malaria transparency clinical trial data carbon innovate drive access medicines european medicines agency adopted research teams given access reduced direct carbon emissions vaccines consumer healthcare products positive scientific opinion malaria gsk trial data since scope since saving seek bring health benefits candidate vaccine mosquirix children million tonnes coe five years people around world open aged six weeks months flexible collaborative approach read breaking barriers effective healthcare opening innovation process accelerate drug discovery areas great read unmet medical need scientific challenge increasing access hiv medication read working address infectious granted royaltyfree voluntary licences non communicable diseases also continue enable generic manufacturers sell hiv increasing transparency medicines significantly reduced prices water work urgent public health emergencies ranked top three transparent zika ebola viruses whilst ftse companies transparency hit water target year early working global community prevent read international corporate political reducing usage since quickly control future disease outbreaks engagement index bring new vaccines medicines reducing child mortality read patients bringing together partners partnership save create new delivery models flexible pricing children reached million strategies increase access products children lifesaving immunisations ethical conduct read treatments interventions since january longer pay hcps speak prescribers medicines vaccines waste produced less waste read versus read engagement employees tackling antibiotic resistance workforce took part global employee advanced antibiotic asset survey providing valuable feedback read moving towards phase iii studies following positive phase ii results read read approach responsible business practice values strong governance creating value society shareholders mission help people feel stakeholder dialogue better live longer researching inform approach developing medicines vaccines improve peoples lives working make products available affordable people need matter live afford investing rd adopting flexible approaches pricing promoting open innovation strengthening healthcare systems growing business extending access medicines ensuring long term commercial success well improving peoples health creating value shareholders delivering economic benefits wider society gsk contributes directly indirectly economic growth countries tax charitable support employment people around world operating responsibly also supports ability attract retain talent manage costs build trust patients consumers low medium customers payers stakeholders influence license operate listening stakeholders welcome engagement range responding stakeholder expectations key areas identified process external stakeholders better understand last several years fundamentally considerable financial operational expectations societal trends teams across changed way operate transforming reputational impacts business gsk regularly engage stakeholders sales marketing practices see shown diagram exchanges customers suppliers promoting open innovation encourage materiality analysis reviewed validated see partners investors research unmet needs see annually engagement stakeholders formal engagement patient advocacy identifying priorities detailed description materiality analysis groups policymakers see identify responsible business priorities available process helps us prioritise listening responding employees undertook formal materiality analysis efforts issues matter also critical help us run business based importance issue business stakeholders effectively retain talented people stakeholders relevance business see goals using internal external inputs sredlohekats ot ecnatropmi hgih gsk responsible business supplement prioritising material issues access healthcare ethical conduct transparency product innovation clinical trials conduct responsible sales marketing intellectual property rights lobbying advocacy practices product safety quality energy climate change tax community investment diversity inclusion economic animal research anticounterfeiting contribution training development waste recycling privacy data security water use human rights labour ethical supplier standards talent attraction reward health safety wellbeing biodiversity security supply importance business success see responsible business commitments align material issues see gsk responsible business supplement approach responsible business practice commitments governance conduct well established longterm responsible boardlevel corporate responsibility governance structure systems business commitments sit across four committee crc oversees responsible key focus areas health behaviour business activities meets four times year board people planet table provide highlevel guidance reviews chairman executive directors independent following shows linked performance commitments nonexecutive directors material issues chairman ceo amongst members nonexecutive director lynn elsenhans regularly review responsible business longstanding member crc took commitments response stakeholder chair sir christopher gent retired feedback business strategy evolves board review resulted two new commitments regarding ethical conduct management key nonfinancial risks corporate corporate administration working third parties updated governed audit risk committee audit risk remuneration nominations responsibility finance transactions commitment access antiretroviral treatment audit assurance team supports committee committee committee committee committee committee hiv subsumed commitment committee providing independent view develop vaccines dont need kept cold board senior management wider goal build products better risk managed across business meet peoples needs longer consistent agreed assurance plan commitment build sustainable supply lines values integrity transparency focus nutrition portfolio instead tackling patients respect people leaders environmental impacts product range motivate employees put core values existing commitments carbon heart decision making applies water waste see everyone gsk wherever work substantially reduced carbon emissions whatever role conducting clinical horlicks report summarise progress research selling medicines interacting commitments patients doctors governments employees must complete code conduct training annually ensure understand integrate values everyday work encourage reporting concerns behaviour goes values speak channels also expect suppliers third parties work share values set public policy statement working third partiescommitments progress commitment progress progress link gsk tracker material issue lla rof htlaeh gsk responsible business supplement user key work needed track progressing well completed innovation unmet medical needs created worlds first open lab noncommunicable diseases africa access healthcare adapt open innovation rd model currently used diseases developing appointed independent scientific advisory board well selected research projects product innovation world apply areas great unmet medical need scientific challenge accelerated development new antibiotics advanced asset developed transparency including infectious disease alzheimers disease partnership moving towards phase iii development collaborative approach dementia intellectual property rights research supporting scientific partnerships novel funding mechanisms accelerate research projects better access medicines vaccines partnered desano pharmaceuticals enable production hiv treatment access healthcare embed flexible pricing strategy innovative business models china number developing countries extended price freeze commitment community investment prescription medicines vaccines increase usage among less able years countries graduating gavi support well pricing access afford products six recently launched new medicines usa parity discount medicines aim supercede building products better meet needs began clinical trial heatstable lowcost inhaled form oxytocin developed access healthcare continue build core range products formats better meet needs collaboration monash university partners submitted regulatory application product innovation people across globe including less able access afford products european medicines agency ema antiseptic gel prevent umbilical cord infections newborns based chlorhexidine solution used corsodyl mouthwash reducing child mortality partnership save children reached million access healthcare continue invest innovative crosssector partnerships reduce child mortality children worlds poorest countries rewarded sustainable scalable healthcare innovations improve underfive child survival rates annual million healthcare innovation award strengthening healthcare infrastructure continued reinvest ldc profits countries training additional access healthcare continue work partners support strengthening healthcare frontline health workers since reaching people million since community investment infrastructure anticipate could improve access healthcare million expanded health worker training beyond ldcs countries subsaharan africa underserved people vs eliminating controlling ntds reached million people million albendazole tablets eliminate access healthcare help eliminate control neglected tropical diseases affect billion lymphatic filariasis control intestinal worms published data highquality hits community investment people including elimination lymphatic filariasis neglected tropical diseases screening two million compounds continued investment rd ongoing product donations contribution collection london declaration neglected tropical diseases fighting malaria received positive scientific opinion european medicines agency malaria access healthcare build year commitment contribute fight malaria candidate vaccine rtss children aged six weeks months launched new product innovation continued rd investment partnerships ground million partnership comic relief fight malaria five endemic countriescommitments progress continued commitment progress progress link gsk tracker material issue lla rof htlaeh eradicating polio delivered million doses oral polio vaccine since access healthcare continue support objective eradicating polio providing contributed billion doses invested inactivated polio vaccine facility belgium vaccines unicef achieved access antiretroviral treatment hiv reached countries worldwide viiv healthcares access programmes access healthcare viiv healthcare continue research new treatments increase granted royaltyfree voluntary licences enable generic manufacturers sell product innovation access medicines care people living hiv around world viiv healthcare products significantly reduced prices together clinton support unaids deliver ambition also health access initiative enabled pharmaceutical company aurobindo file work communities combat stigma discrimination associated hiv application us fda generic approval dolutegravir ruoivaheb ruo gsk responsible business supplement user key work needed track progressing well completed ethical conduct employees completed mandatory annual training code conduct ethical conduct continue strengthen values based culture training people extended training complementary workers strengthened training standards expected encouraging reporting concerns embedding external certification members ethics compliance team values way measure employee performance promoting values sales marketing completed global rollout changes sales team compensation longer pay ethical conduct continue drive valuebased approach sales marketing practices across healthcare professionals speak prescribers medicines responsible sales world interests consumers patients core marketing transparency clinical research wellcome trust took management panel external independent experts transparency clinical transparent possible clinical trial data including publishing review proposals access data wwwclinicalstudydatarequestcom important trial data clinical study reports without patientlevel data outcome trials medicines step towards creating independent datasharing system includes studies intellectual property rights conducted gsk within appropriate process making available across industry academia also met commitment make available researchers access anonymised patient level data scientific enquiry global studies going back formation gsk studies rigorous patient consumer safety recognised collaboration informatics company epidemico monitor publicly anticounterfeiting continue ensure interests safety patients consumers paramount available information social media gain insights adverse effects medicines product safety quality importance way design undertake clinical trials product quality extended supply chain serialisation programme fingerprint across packaging lines assurance monitoring reporting adverse events ongoing product usage verify products anywhere supply chain help combat counterfeiting minimising animal testing used fewer animals continuation downward trend nine years animal research rigorously challenge need animal studies work minimise impact animals used rodents animal welfare investing development alternative studies sharing animal based data commitment updated previous commitment ended commitments progress continued commitment progress progress link gsk tracker material issue ruoivaheb ruo promoting human rights labour rights included comprehensive new programme strengthen management human rights labour address un guiding principles business human rights across third party risks supply chain became living wage accredited employer uk operations supplier relationships ensuring ethical interactions ranked top three transparent ftse companies transparency ethical conduct demonstrate gsk interactions patient advocacy groups political international corporate political engagement index produced new global lobbying advocacy stakeholders conducted appropriately ethically transparently standard interactions patient organisations practices tax economic contribution working third parties introduced comprehensive new programme strengthen management third party ethical conduct seek work third parties share commitment high ethical risks supply chain identified highrisk suppliers must undergo human rights labour standards operate responsible way performance gaps identified assessment responsible business policies practices assessed around appropriate commit working third party improve performance highrisk distributors elpoep ruo creating inspiring healthy workplaces employees ever shared views employee survey response health safety continue create working environment inspires people grow perform rate refreshed simplified health safety standards exceeded graduate wellbeing healthy resilient way recruitment target hiring graduates postgraduates onto future leaders training development esprit programmes globally promoting inclusion diversity welcomed women accelerating difference programme supports diversity inclusion continue promote inclusion diversity globally gsk career advancement female leaders partnered uk governments disability confident campaign raise disability awareness across company community volunteering create change enabled employees countries provide million worth skilled community investment extend volunteering opportunities bring positive change communities services nonprofit partners pulse volunteering programme since global health providing individual development participants line managers colleagues agreed experience helped develop skills performance tenalp ruo gsk responsible business supplement user key work needed track progressing well completed carbon value chain carbon footprint grown largely due continued growth sales energy use climate reduce overall carbon footprint vs carbon propellantbased inhalers direct carbon emissions declined bringing total change neutral value chain reduction five years scored environment disclosure cdp water hit water target year early reducing usage since saving water use reduce water impact across value chain vs million water use whole year partnered energy resource institute develop water saving initiatives rural indian communities waste produced less waste compared previous year waste recycling reduce operational waste vs manufacturing rd sites achieved zero waste landfill gsk responsible business supplement h ealth positive action programmes target key affected populations reach greatest risk hiv infection image courtesy international centre research womengsk responsible business supplement health approach medicines vaccines consumer health highlights products improving quality life patients increasing access hiv medication consumers around world however following agreement medicines many people still getting treatments patent pool extended access dolutegravir need challenges include affordability countries adults hiv fact still many diseases without open innovation developing world live treatments underresourced health systems shared data researchers addressing challenges tackling compounds showed signs activity read barriers affordability accessibility neglected tropical diseases flexible pricing approach support research new treatments within outside gsk reducing child mortality work key partners stimulating open innovation target areas unmet medical partnership save need neglected tropical diseases children reached million fighting malaria people including million children mainly affect developing world european medicines agency adopted lifesaving immunisations treatments noncommunicable diseases cancer positive scientific opinion malaria interventions since diabetes candidate vaccine mosquirix read recommended pilot rollout also strengthening healthcare systems countries subsaharan africa around world continued reinvestment profits generated launched new million partnership flexible pricing worlds poorest countries training comic relief fight malaria frontline health workers regions cohi ms mye ita mr ew ne te ox e n yee ad r u rp cri oc ue n f tr iee sz e read strengthen health systems uns new global goals sustainable graduating gavi support read development sdgs health explicitly included maintained commitment cap goal number three ensure healthy lives prices patented medicines strengthening healthcare infrastructure promote wellbeing ages vaccines least developed countries trained additional frontline vaccine historic achievement support tackling biggest developed world prices six health workers since welcome addition arsenal global health challenges newborn recently launched new medicines least developed countries reached preventive tools fight mortality malaria extending benefits usa priced parity discount people million since malaria commend glaxosmithkline medicines aim supercede products people regardless demonstrating resilience ingenuity live ability pay read developing valuable asset ray chambers un secretarygenerals special envoy read health agenda malariagsk responsible business supplement health focus responding ebola zika humanitarian emergency response saw critical public health emergency gsk committed working partners every year millions people displaced unit began uk outbreak ebola west africa help ensure proactive approach disasters emergency situations extended asia pacific region usa demanded urgent response planning global health threats crises devastate families leaving recently announced partnership save impact continued well providing respond faster event similar without access adequate food children national center humanitarian support affected regions gsk crises example worked shelter healthcare disaster preparedness help communities accelerated development candidate us governments biomedical advanced better plan protect care children gsk works partners humanitarian vaccine ebola unprecedented rate research development authority barda event disaster organisations prepare respond trials underway since inception emergency situations instances collaboration critical fasttrack development lifesaving able fast track development ebola vaccines others contribute vaccine due fact many different donating cash products employees organisations including national institutes time also invest longterm rebuilding health usa wellcome reconstruction aftermath disaster trust uk government worked gsk worked save children together common goal create strategic operational framework closely monitoring outbreak humanitarian action mobilise zika virus brazil since began resources expertise organisations autumn reached strengthen response included partners collaborators brazil across providing seed funding help save world assess situation feasibility children establish emergency health unit potential vaccine development also team specialist health workers evaluating existing technology platforms deliver basic healthcare within hours believe could potentially suitable disaster strikes working zika virus vaccine experience particularly developing ebola vaccine useful anna pantelia event future outbreaks recognise save children global community must improve capacity prevent quickly control unpredictable disease outbreaks help avoid devastating consequences human health economies global security aubrey wade donated support efforts save children address global refugee crisisgsk responsible business supplement health innovation unmet medical needs breaking open innovation approach tres cantos researchers screened approach based three principles access library two million compounds barriers effective compounds data greater flexibility signs activity kinetoplastids healthcare opening intellectual property partnerships share group parasitic diseases estimated infect expertise processes infrastructure approximately million people developing innovation process world shared hits identified diseases developing world accelerate drug discovery researchers encourage research open innovation model continues advance field within outside gsk areas great unmet research diseases developing world builds similar exercises already ddws malaria tuberculosis tb carried malaria medical need neglected tropical diseases ntds scientific challenge dedicated research centre tres cantos spain work exclusively developing new read innovative medicines diseases eliminating controlling developing world supported collaborating ntds organisations including wellcome trust bill melinda gates foundation noncommunicable diseases ncds took unprecedented step also using open innovation model opening facilities external scientists accelerate research ncds africa ncds creating worlds first open lab visiting include worlds biggest killers scientists work projects africa ncd open lab appointed cancer diabetes heart disease chronic commitment adapt open innovation accessing gsks expertise resources independent external scientific advisory board respiratory diseases like copd healthcare rd model currently used diseases capabilities five years since opened chaired leading african scientist research africa focused communicable developing world apply areas open lab built portfolio research provide input strategy first research diseases ncds emerging great unmet medical need scientific projects supported visiting scientists projects selected eight sub continents next biggest killers recognising challenge including infectious disease resulted scientific publications several saharan african countries lab gap created africa ncd open alzheimers disease promising drug discovery leads additionally also support researchers south african lab work partnership major projects contributed towards generating institutions partnership medical funders academic groups governments million follow grants enable research councils south africa uk conduct ncd research africa effort researchers ddw research progress overview completed critical achieve world health assembly uk also partnering medical goal reduce avoidable mortality ncds research council five universities increase understanding experimental medicine initiative explore new unique attributes ncds african patients therapies eminent open innovation research initiative aims support ten experimental medicine projects inflammatory diseases chronic obstructive pulmonary disease copd fibrosis approach ncds see policy papergsk responsible business supplement health innovation unmet medical needs continued research tuberculosis tackling antibiotic resistance research tuberculosis tb stalled increasing resistance existing antibiotics alzheimers dementia last years yet million people many emerging urgent public health crisis dementia one leading causes living poverty contracted disease drug resistant infections responsible disability dependency among older million died result deaths year problem people globally alzheimers disease time emergence spread multi exacerbated scientific economic prevalent cause dementia drugresistant tb presents increasing public obstacles discourage research develop extending open innovation model tackle health threat current treatments typically new antibiotics challenge focus publicprivate less effective toxic costlier partnerships new collaborative models despite challenges committed led orchid alliance open collaborative advancing research field became founding partner model tuberculosis lead optimization research unit focused developing million investment uk address urgent medical need fouryear next generation antibiotics governments dementia discovery fund multisector partnership cofunded active pipeline potential new medicines global fund dementia research european union completed aimed development advanced asset fund designed speed discovery develop new medicines drugresistant topoisomerase inhibitor gepotidacin development new treatments dementia tb make available patients quickly gsk developed identify promote new avenues efficiently collaboration us governments research around world biomedical advanced research development work alliance included repurposing also continue participate authority barda asset novel betalactam compounds potential anti us accelerating medicines partnership mechanism action potential tubercular drugs using tb hits alzheimers uk dementia platform address multiple indications moving compound collection identify targets lead imis pharmacog project towards phase iii studies following positive january signed declaration future tb drug discovery programmes creating develop new tools testing candidate phase ii results pharmaceutical diagnostics portfolio lead compounds moving two drugs treat alzheimers companies committing work governments hits precandidate selection stage collaboration barda one parallel develop sustainable economic several partnerships involved also advancing phase ii clinical models antibiotics ensure sustainable governments scientific institutions trial candidate tb vaccine developed supply medicines future commitment ended companies accelerate development partnership aeras funding replacing new new antibiotics another key publicprivate bill melinda gates foundation commitment focus important collaboration field active global health challenges including members innovative medicines tackling antibiotic resistance initiatives newdrugsbadbugs initiative diseases developing world launched address key issues associated investment development new antibiotics uk governments dementia discovery fundgsk responsible business supplement health better access medicines vaccines working make affordability low middleincome supply gavi vaccines cervical middleincome countries many people countries cancer cervarix pneumococcal disease still living poverty flexible pricing medicines vaccines six billion people live emerging markets synflorix introduced approach enables people access available affordable million begin using healthcare countries committed freezing products halving price seretide first time next five years flexible prices developing countries graduate inhaler devices accuhaler evohaler people need pricing strategy seeks meet healthcare gavi support continue india increased sales volumes matter live needs providing products lower prices purchase vaccines significantly discounted yearonyear extend access way prices decade graduation also philippines gsk introduced card afford global footprint broad product offering allows supplied million lowcost doses synflorix coupon patient programme offering discounts us sell high volumes products gavi doses mdecins sans selected products frontires immunise children caught crises patients accessed since capped prices products including antibiotics augmentin patented medicines vaccines least extended tiered pricing model zinnat well seretide inhaler developed countries ldcs developed include prescription medicines develop programme world prices long manufacturing costs pricing strategies based countryspecific covered also tiered pricing circumstances patient affordability also participated groundwork approach products countries pay local healthcare system social dialogue multistakeholder platform alongside price based gross national income economic actors whilst increased national representatives colombia ghana commitment embed flexible gni per capita access products philippines thailand vietnam improve pricing strategy innovative business gsk pioneered tiered pricing model strategy know work evidencebased decisionmaking health models prescription medicines improve access vaccines enable bangladesh example sales gsks brand systems low middleincome countries vaccines increase usage among lowincome countries roll national cefixime grown four years resulting groundwork framework released less able access afford products immunisation programmes offer lowest since reduced price help people outlines plan governments access oral antibiotic industry enable people obtain medicines prices vaccines organisations gavi need price afford vaccine alliance supports countries gni per head less since un high level panel innovation access progress overview progressing well supplied nearly million doses also issue report ceo andrew rotarix vaccine gavi enabling ldcs witty sits panel convened launch immunisation programmes combat un secretarygeneral ban kimoon rotavirus gastroenteritis common cause diarrhoea childhood mortalitygsk responsible business supplement health better access medicines vaccines continued affordability developed countries building local capability capacity supporting community access healthcare affordability also hinder access people building local capabilities improves access targeted product financial donations giving developed countries broaden access developing countries providing patients help local global partners provide community products markets consumers locally relevant products access healthcare global flexible approach retaining returns enhancing domestic manufacturing community investment totalled million cash investment innovation example capacity capability compared million product usa six recently launched new increasing local access supply support included inkind medicines priced parity discount important part commitment africa time pulse medicines aim supercede cash donated million management continued evaluate options cash communities worldwide including usa offer various types patient manufacturing nigeria also total million health wellbeing assistance help ensure appropriate access investing academia africa education programmes includes medicines gsk programmes collaborating royal society donating million strengthen healthcare eligible patients prescription chemistrys pan african chemistry network infrastructure ldcs primarily training drug coverage medicare part universities across subsaharan africa community health workers see prescription drug plan offer train scientists collaboration specialty product assistance eligible insured aims support development skilled product donations donated medicines patients result new coverage options workforce turn support vibrant valued million support includes available following affordable care act local healthcare economies patient assistance programmes patients insured fewer requiring million albendazole tablets fight announced plans establish patient assistance programmes pap lymphatic filariasis soiltransmitted helminths new global headquarters asia however part commitment access see product donations support singapore started work million continue provide services help patients humanitarian aid distributed pharmaceutical factory india operational understand alternative coverage options partners americares direct relief ima world factory manufacture eight billion tablets paps provided prescribed gsk health map international project hope one billion capsules antiinflammatory medicines vaccines valued gastroenterology medicines per year expertise employees volunteered time patients indian market skills expertise worth million reached agreement uk brazil collaborating fiocruz government make britain first country develop vaccines tackle countrys nationwide vaccination programme health priorities india joint venture meningitis b potentially deadly infectious biological e developing combination disease offers fair value national health vaccine six diseases one viiv service ensuring gsk continue healthcare signed innovative invest creating new treatments vaccines manufacturing partnership desano pharmaceuticals manufacturer provide hiv treatment dolutegravir competitive gsk values product donations cost goods believe truer reflection cost gsk wholesale acquisition price china countries cost often used pharma industry valuing product donations need greatest total value prescribed gsk medicines vaccines provided paps based wholesale acquisition cost gsk responsible business supplement health building products better meet needs developing making medicines vaccines consumer developing new formulations formats smaller pack sizes make products products available appropriate formats exploring ways existing affordable new formulations important part strategy increase access products reformulated tackle different sell smaller sachets products formats overcome healthcare better meet diverse needs health challenges emerging markets order make patients healthcare systems worldwide affordable example sensodyne accessibility barriers partnership save children toothpaste philippines horlicks developing vaccines medicines investigating use skin emollient extend reach dont need kept cold containing sunflower seed oil reduce nutritional supplement india singleunit inhaler products ventolin rotacaps lifesaving products vaccines need kept cool risk infection dehydration hypothermia rotahaler devices help patients living c c storage distribution caused severe acute malnutrition asthma copd manage cost remain effective developing countries children also submitted regulatory treatment buying little time enables maintaining cold chain right application european medicines agency patients particularly receive wages patient challenging antiseptic gel prevent umbilical cord daily weekly basis access critical infections newborns reformulated partnership bill melinda medication ventolin rotacaps rotahaler chlorhexidine solution used gates foundation reformulating critical devices registered countries corsodyl mouthwash see liquid component used rtss candidate expanding reach patients philippines work reduce child mortality malaria vaccine enable remain stable indonesia vietnam nigeria kenya three years even temperatures c combining one vaccine treatment commitment continue build core june demonstrated stability extend coverage reduce number range products formats better one year c month doses need transported meet needs people across globe c aim integrate thermostable administered health workers simplify including less able access formulation global malaria strategy complex drug regimens patients afford products make easier transport store vaccine flu vaccine protects people four hot regions like subsaharan africa strains influenza rather three single people risk disease dose bangladesh began clinical study progress overview progressing well medicines also need refrigerated test fourdose vial synflorix oxytocin manufactured hormone used pneumococcal vaccine supply gavi reduce excessive bleeding birth successful new format reduce single biggest cause maternal mortality storage space cold chain capacity liquid oxytocin hard access developing required transport use vaccine countries lack proper refrigeration viiv healthcare investigating trained healthcare workers administer combination multiple drugs provide injections collaborating monash treatment options simplify complex university australia partners drug regimens people living hiv viiv develop heatstable lowcost inhaled form healthcare dedicated paediatrics group oxytocin began clinical trial focused developing antiretroviral treatments new dry powder formulation adapted infants children see gsk responsible business supplement health reducing child mortality vaccines approximately children five using insights ontheground knowledge pulse volunteering programme die every day many preventable causes save children working see gsk employees medicines pioneering due social economic inequalities reformulate antiseptic chlorhexidine solution volunteered save children since partnership save underfive mortality lowincome countries used gsks corsodyl mouthwash gel also encourage employee fundraising times higher highincome countries prevent umbilical cord infections issue children since partnership began gsk employees exacerbated developing countries many committed helping save one million raised million contributing urgent births take place home without proper childrens lives worlds poorest countries increased million matched health care october submitted effort reduce child groundbreaking partnership regulatory application european medicines funding gsk money raised used save children efforts include developing support health programmes kenya agency approved use offer mortality globally childfriendly medicines widening immunisation drc well save childrens antiseptic gel notforprofit price coverage accelerating access treatments humanitarian relief efforts local programmes share knowledge others strengthening healthcare systems countries around world manufactured locally read work commitment important contribution save children pages efforts reduce child mortality un global goals sustainable development vaccines immunise children critical end preventable deaths newborns programmes save children reducing childhood mortality children five years age democratic republic congo drc kenya work gavi provide reducedprice aim establish models replicated partnering help save one million vaccines help protect million developing countries example childrens lives children diseases rotavirus drc children year partnership save pneumococcal disease commitment continue invest innovative die reaching fifth birthday children combining capabilities crosssector partnerships reduce child delivering essential services neonatal also committed donate rd supply chain procurement vaccines mortality maternal child health kenya million tablets albendazole year charitys expertise working supporting charitys newborn child survival support whos goal deworm vulnerable children together delivering programme trained community children countries intestinal tangible results date reached health workers set community health units worms endemic see progress overview track million children underfives refurbished maternity centres fully immunised children many health worker training programmes treated diarrhoea malaria february announced winners see focus reducing child pneumonia one million children third annual million healthcare innovation maternal mortality rural communities screened malnutrition award set gsk save children example nepal work care reward sustainable scalable healthcare international government improve innovations resulted tangible maternal neonatal reproductive health improvements underfive child survival improving skills frontline health rates winners include innovations workers providing health equipment strengthening health systems community enabling local communities feedback programmes treatment strategies health centres perform quality africa asia south america overall services provided support winner digital immunisation system health workers nepal trained developed path south vietnam reaching one million beneficiariesgsk responsible business supplement health strengthening healthcare infrastructure reinvestment least world face estimated shortfall amref health africa supported elearning children mozambique nearly million frontline health workers lack training nurses midwives registered mvaccination pilot developed countries ldcs trained health workers already presents tanzania uganda programme vodafone seeks improve trained fundamental barrier accessing quality healthcare vaccination rates using mobile phones parents gsk supporting un one million community people worlds poorest countries caregivers receive updates phones frontline health workers health workers campaign advocates remind vaccinations due partners training frontline health recruitment formal recognition ministries supporting million workers supporting community education health one million community health workers vaccination visits recorded underserved people advocating increased investment health funding pilot train health workers addition healthcare workers responsible system strengthening ghana campaign aims showcase recording vaccination stock levels catalyse investment programme refrigerator temperatures weekly basis reinvesting healthcare phone average five stock ldcs operate reinvest increase access healthcare updates three cold chain updates per week profits sales pharmaceutical deliver longterm economic growth across africa recorded facilities december consumer healthcare products train expanded health worker training beyond service expanded facilities educate community frontline health workers ldcs ghana kenya nigeria countries since reinvested supporting amref health africa train health funding usaid gavi randomized million ldc profits countries workers kenya managing diabetes control trial measure impact pilot training frontline health workers childhood asthma also working assess cost effectiveness inform decisions commitment continue work partners including midwives nurses community save children build capacity scaling programme mozambique support strengthening healthcare health workers volunteers frontline health workers across three nigerian african countries infrastructure anticipate could improve turn reached million people states reach children also contributing joint initiative access healthcare million underserved five mothers end ensure sustainability reinvestment international telecommunications union people vs aim trained health workers programmes tailored meet specific assist governments use mobile technology benefitting millions underserved patients community needs align government health prevent treat noncommunicable diseases priorities working partners amref health partnering develop new healthcare developed developing countries progress overview progressing well africa care international save children delivery models initiative targets risk factors conditions focus training frontline health workers exploring technology new smoking hypertension diabetes poor diets educating communities basic preventative business models used transform costa rica example campaign using health build capacity improving health way healthcare delivered developing text messages help people stop smoking facilities equipping training centres advocating countries around world encouraged participants quit improved policies increased investments gsks threeyear partnership barclays began working marie stopes governments support seeks develop new business models international ngo pilot scalable care international trained midwives increase access healthcare stimulate womens health intervention programme local communities bangladesh economic development zambia bangladesh madagascar sierra leone formally accredited salaried government worked together launch oneyear pilot screen prevent treat cervical cancer social enterprise care international programme target women aged save children successfully lobbied mali train community entrepreneurs sell health expand roll government recruit health professionals products doortodoor cervarix cervical cancer vaccine young girls demonstrating effectiveness community health worker training programmegsk responsible business supplement health eliminating controlling neglected tropical diseases partnering ntds group communicable diseases albendazole donation researching new treatments prevalent developing countries pledged donate albendazole long scale complexity ntds requires others free millions affecting one billion people nearly one needed help eliminate lf mosquitoborne open flexible approach innovation people debilitating six people worldwide suffers least worm disease causes disfiguring swelling addition rd group dedicated one ntd debilitating effects including limbs genitals known elephantiasis ntds diseases developing effects neglected tropical disability disfiguration death also committed providing million world ddws prioritising research diseases ntds detrimental impact health albendazole tablets year help treat school area tres cantos open lab see economies worlds poorest countries age children risk intestinal worms gsk also founding member wipo soiltransmitted helminths endemic research open innovation platform together partners london seeks accelerate development new declaration ntds committed donated million albendazole better treatments ntds controlling eliminating least tablets lf elimination million tablets ntds partnership major treat intestinal worms total donated open innovation process resulted pharmaceutical companies un organisations nearly six billion tablets years reaching publication highquality hits academics ngos national governments million people including million ntds screening two million released third annual report scorecard school aged children compounds collection scientists progress made towards working tres cantos also made progress commitment help eliminate control ten targets challenges remain contribution developing first preclinical candidate ntds affect billion people focuses largescale donation albendazole treat visceral leishmaniasis promising including elimination lymphatic filariasis efficient forecasting manufacturing shipping precandidate drug combat chagas disease lf continued investment rd donated products global research advocacy ongoing product donations contribution london declaration ntds donation albendazole enables deworming school age children endemic countries also extensive rd effort ntds focuses african sleeping sickness progress overview progressing well chagas disease leishmaniasis efforts hope make significant contribution new targets end ntds form part un global goals sustainable development albendazole tablet donations total since tablets lf elimination tablets treat intestinal worms total gsk responsible business supplement health fighting malaria years research child africa dies malaria every two using open innovation approach partnerships fight malaria minutes age five malaria addition significant investment since supported africa closer ever poverty closely linked communities development vaccine prevent malaria malaria partnership promote use existing making available highest risk disease often also continuing research new interventions bed nets indoor residual least access prevention diagnosis better treatments contract spraying antimalarial treatments worlds first vaccine treatment disease research resulted continued partnerships devastating disease discovery preclinical candidate last years together partners amref health africa save children effective current malarial parasites working develop vaccine train health professionals community health protect young children deadly parasite stimulate external drug discovery research workers tanzania kenya respectively reached significant milestone malaria published promising also continued work fhi journey european medicines agency hits compound collection carter center combine interventions adopted positive scientific opinion control malaria ntds ghana nigeria also working mmv malaria candidate vaccine mosquirix rtss faiths act sierra leone train progress development tafenoquine children aged six weeks months faith leaders become malaria ambassadors drug treat prevent p vivax malaria recommended rtss strain occurring primarily south south december launched new introduced pilot rollout east asia latin america horn africa partnership comic relief uk charity actively working financing bodies phase iii trial programme currently fight malaria strengthen health systems commitment build year malaria vaccine clinical trials partnership investigating tafenoquine adult patients million partnership created commitment contribute fight including path gsk generate support p vivax malaria million donation gsk million malaria continued rd pilots finalise design comic relief make grants frontline investment partnerships ground pilot implementation programme organisations five malaria endemic countries complements interventions global gsk developed rtss partnership health funders grassroots organisations path malaria vaccine initiative funding collaboration aim support progress overview progressing well bill melinda gates foundation target reduce malaria cases vaccine candidate targets malarial parasite deaths least support p falciparum prevalent sub global goals sustainable development saharan africa trials shown use along bed nets insecticides help protect regions vulnerable children gsk committed supply rtss notforprofit price price cover cost manufacturing vaccine together small return around five per cent reinvested research developmentgsk responsible business supplement health eradicating polio using vaccines polio infectious viral disease mainly affects children known cure many technologies support instances cause lifelong paralysis eradication polio past years world poliofree gsk played key role achieving partnership organisations committed supporting whos goal completely eradicate disease september announced polio longer endemic nigeria follows milestone india declared poliofree good news however virus remains endemic two countries commitment continue support afghanistan pakistan without eradication objective eradicating polio global threat polio remains new providing vaccines unicef outbreaks confirmed madagascar achieved global polio eradication initiative gpei supply oral polio vaccine opv countries need progress overview progressing well delivered million doses opv inactivated polio vaccine ipv replacing since contributed opv countries disease billion doses expect meet full eradicated prevent reemergence threeyear contractual commitment gpei disease already supply ipv developed delivering million doses countries investing new ipv facility supplied million another million belgium due begin production doses oral polio vaccine scientists recommended formed qualivax joint venture transition opv targets two disease indian pharmaceutical company biological e strains instead usual three removing create combination vaccine includes type strain detected inactivated polio virus ipv vaccines five since small risk disease diseases single dose expect reemerging vaccine eliminated vaccine available following line strategy ready eradication polio combination vaccine successful switch twostrain vaccine important tool help prevent april also stockpiled large resurgence disease particularly amounts opv kept available use developing world unicef event outbreakgsk responsible business supplement health access antiretroviral treatment hiv research worldwide million people living hiv increasing access hiv treatment care improving outcomes key affected adults children getting extending access hiv treatment care populations collaboration treatment supporting efforts work priority particularly lowincome countries stigma remains one biggest barriers developing increasing towards universal coverage priority nearly people affected hiv live people getting tested disclosing hiv status develop new medicines hivaids ensure viiv healthcares access programmes reach starting treatment since access treatments accessed people need countries worldwide royaltyfree voluntary supported hiv community fight stigma hivaids licences enable generic manufacturers sell discrimination promote healthcare access products donor agencies public sector working community based delivering new treatments programmes significantly reduced price organisations stakeholders tivicay dolutegravir first approved us fda available countries following agreement medicines target efforts key affected populations triumeq combined antiretroviral drug patent pool mpp unbacked organisation reach greatest risk hiv infection approved available encourages voluntary licencing patent programmes include million positive pooling viiv healthcare introduced first action children fund support prevention innovative formulations delivery methods ever mpp licence tiered royalty system mothertochild transmission raising vital people living hiv viiv healthcare tailored national gdps strategy extends awareness hiv prevention testing care working janssen pharmaceutical research access dolutegravir countries among adolescents girls women men commitment viiv healthcare company develop twodrug single tablet adults hiv developing world live sex men transgender community continue research new treatments regimen combining dolutegravir rilpivirine paediatric formulations drug example announced us million increase access medicines care patients already virally suppressed countries children million fouryear accelerate initiative people living hiv around world also exploring combining cabotegravir hiv live catalyse community support black gay support unaids deliver rilpivirine two longacting formulations bisexual men us cities hardest hit hiv ambition also could administered much less frequently also helping improve access work communities combat stigma existing medicines making easier facilitating approval process generic antiretroviral treatment coverage often lower discrimination associated hiv people adhere treatment addition versions dolutegravir partnership children adults viiv healthcare investigating use cabotegravir clinton health access initiative enabled dedicated rd work stream develop prevention highrisk populations indian pharmaceutical company aurobindo file formulations therapies better suited infants application us fda generic children age developed part ongoing research antiretroviral progress overview progressing well approval dolutegravir fda approval paediatric tastemasked formulations abacavir treatments support clinical generic dolutegravir could supplied lamivudine improve adherence children studies involving patients across presidents emergency plan aids relief therapy since receiving tentative approval africa asia studies address licensed countries outside usa fda treatment partners areas patients regions including us europe tivicay triumeq mylan clinton health access initiative prevention mothertochild transmission available patients relevant working make available tb coinfection paediatrics adolescents national health services countries covered license agreement findings studies used inform local global hiv treatment programmes see viiv healthcare website improve access patients regions information including new series policy people living hiv know hiv status documents key issues diagnosed receive sustained antiretroviral therapy receiving therapy undetectable viral loadgsk responsible business supplement behaviour january longer pay hcps speak prescribers medicines vaccinesgsk responsible business supplement behaviour approach driven values everything highlights developing testing manufacturing working third parties new medicines engaging governments introduced comprehensive new appropriate policies programme strengthen management environmental social risks using rigorous standards controls transparency clinical trial data supply chain identified around prioritise patient safety transparency acting high risk suppliers distributors integrity research clinical trials given research teams access must undergo assessment continuously monitor report clinical trial data enabling programme potential adverse effects medicines research maximising contribution vaccines prescribed physicians made thousands volunteers patients participating studies used patients expect employees suppliers sales force puts patient live values mandatory annual training needs first ensures people know code conduct january completed rollout read measure performance changes way sales teams deliver deliver read compensated globally pharmaceutical line values medical representatives longer increasing transparency significantly changed commercial individual sales targets gsk ranked among model lead industry way sell ethical conduct top three transparent ftse market medicines ensure patients people completed mandatory read companies transparency internationals needs come first pharmaceutical medical annual training code conduct corporate political engagement index representatives world longer including complementary workers top think interaction individual sales targets instead required take training pharmaceutical industry doctors open assessed compensated based first time critique interaction industry knowledge quality service deliver health professional community healthcare professionals hcps needs open transparent broader business performance read one core values respect people sir michael rawlins human rights fundamental gsk chair medicines healthcare signatory un global compact read products regulatory agency exploring implement un guiding principles business human rights across value chaingsk responsible business supplement behaviour focus ethics compliance academy values dictate behave guide nick hirons head global ethics decisions make global ethics compliance said wanted go beyond compliance team play major role embedding training take people development valuesbased culture providing tools journey compliance professionals ethics establish robust internal controls create compliance experts goal help ethical culture people feel comfortable participants help business make values raising concerns based decisions recognise confidently navigate ethical grey zones introduced new ethics compliance academy provides indepth academy building network training external certification members informed engaged effective ethics team worldwide aim innovative compliance officers ran five academy model strengthen compliance ethics sessions employees countries promoting common approach ethics agreed learned new skills compliance across business agreed academy valuable use time five days interactive activities case studies presentations internal plan develop less specialised version external experts participants learn academy senior leaders employees apply gsks values practically day day legal human resources audit functions basis detect potential risk areas enhancing knowledge ethics across business completion compliance create even stronger course participants must successfully pass ethical culture across gsk examination receive leading professional ethics compliance lpec certification issued ethics compliance initiative eci nonprofit organisation completed course achieved pass rate average score ran academy sessions employees countriesgsk responsible business supplement behaviour ethical conduct guided training employees expectations embedding values performance train people put values measurement values integrity practice make right choices living values one six expectations transparency focus faced ethical dilemmas code use measure employees performance conduct dedicated online resource centre global performance system patients respect provide guidance tools need puts emphasis way employees people everything apply values everyday activities achieve results rather results wherever work around world part continued focus embedding values performance employees completed management extended existing mandatory annual training code recoupment programme cover approximately conduct online course available senior managers globally also languages includes training fundamentally changed compensation model values ethical leadership antibribery sales teams focus patient needs corruption reporting issues see promoting values concerns sales marketing practices increased managers accountability antibribery corruption ensure employees take part commitment continue strengthen training extended mandatory zero tolerance bribery corruption valuesbased culture training training complementary workers form antibribery corruption people standards expected first time employees fail complete abac programme includes risk assessments encouraging reporting concerns course may face disciplinary action standards additional training people embedding values way defined permitted local labour laws working high risk areas measure employee performance people received written verbal employees completed training rolling new simpler warnings failing complete course framework engage train third parties required time frame even based risk profile granted extension progress overview progressing well employee survey respondents agreed work environment encourages ethical behaviour even face pressures meet business objectivesgsk responsible business supplement behaviour ethical conduct continued reporting investigating misconduct disciplinary action centrally track misconduct allegations disciplinary action taken employees employees disciplined concerns security incidents received fail act line policies breakdown types policy violation speak channels monitoring employees disciplined policy violations routes received types policy violations reports allegations majority see chart remained broadly attendancepayroll attendance payroll remains g ood manufacturing practices good distribution practices speak channels offer people biggest type violation total ravel expenses within outside gsk opportunity ask followed good manufacturing marketing promotional activities questions voice concerns anonymously practices travel confidentially independent third expenses violations increased code conduct party phone online due increased frequency monitoring local work regulations unauthorised absenteeism concerns raised reviewed total disciplined received verbal ehssafety formal investigations initiated warnings employees received falsification documents response allegations five documented warning training completion frequent categories allegation dismissed agreed leave employee performancerelations product company voluntarily highest number promotion interactions hcps fraud dismissals related travel expense abac policy violations accounted dismissals followed dismissals related code conduct violations attendancepayroll violations like many pharmaceutical companies faced various complex product liability antitrust patent litigation well investigations operations conducted various governmental regulatory agencies details ongoing investigations set annual reportgsk responsible business supplement behaviour promoting values sales marketing practices transformed creating sales force puts patient changing way engage hcps disclosing payments made hcps needs first remain committed ongoing dialogue gsk committed disclosing payments way compensate january completed rollout scientific community supporting make hcps healthcare organisations salesforce engage changes way sales teams medical education making changes individual aggregate basis already compensated globally pharmaceutical transform modernise way engage several countries including australia healthcare professionals medical representatives around world hcps january longer denmark france japan netherlands ensure patient needs longer individual sales targets instead pay hcps speak prescribers portugal slovakia uk us line incentivised based technical prescription medicines vaccines locally agreed government industry come first knowledge quality service deliver continue pay hcps providing services association codes plan disclose healthcare professionals hcps support participating clinical research payments aggregate basis canada improved patient care broader set payments governed rigorous controls support increased transparency business performance measures sales based fair market value countries industry associations teams listening customers needs gsk also changing way supports medical governments establish specific guidelines using right gsk resources help support education longer playing role choosing disclosure example new code delivery improved patient care healthcare professionals sponsored disclosure payments hcps usa approach generated strong attend scientific congresses instead european federation pharmaceutical positive customer feedback survey company provide funding independent industries associations efpia requires commitment continue drive values us hcps july gsk ranked first professional bodies allocate funding payments made st january based approach sales marketing trust customer value second time individuals another industry first onwards reported annual basis practices across world interests row simplifying system resulted also support independent medical education first reports expected published consumers patients core significant increase engagement levels among providing grant funding recognised education june us sales teams employee survey providers programmes independent respondents agreed us pharma influence programme content making changes necessary compete provide information medicines progress overview progressing well said proud work gsk vaccines way hcps want sales marketing employees along want making significant investments relevant third parties must follow code digital platform capabilities well practice promotion customer interactions inhouse medical capabilities markets gsk experts speaking hcps found highly effective informative canada stopped payments hcps early gsk expert speakers delivered number medical product information sessions june external hcps attendees commented strong scientific knowledge communication skills gsk speakersgsk responsible business supplement behaviour transparency clinical trial data advancing medical safety effectiveness new medicines also first pharmaceutical company initially proposals reviewed panel must demonstrated clinical trials sign alltrials campaign trials external independent experts appointed science patient care providing greater access data registered results reported gsk wellcome trust took providing greater access trials regardless whether results might campaign received support investors management panel appointed new considered positive negative allows representing trillion assets members important step towards clinical trial information others conduct research also usa europe australia achieving vision independent data helps us ensure maximise contribution sharing system includes studies across committed share detailed made thousands volunteers industry academia discussions patientlevel data sit behind clinical trial patients participating studies groups driving progress results support research harvard multiregional clinical trials centre since online clinical study advance science improve patient care wellcome trust arnold foundation register make available information data anonymised protect patient national academy medicine trials including summaries results confidentiality access researchers must submit research proposals independent past number years led review panel ensure data used industry sharing information data commitment transparent possible valid scientific enquiry trials advance medical science patient clinical trial data including publishing care first company make clinical clinical study reports without patientlevel study reports csrs publicly available data outcome trials medicines formal reports basis submissions conducted gsk within appropriate regulatory agencies include detailed process making available researchers research proposals information design methods results access anonymised patient level data submitted access trials post clinical study scientific enquiry gsk trial data register patients personal information removed register includes three years system set gsk summaries trial results csrs researchers request access data progress overview completed wwwclinicalstudydatarequestcom lists global clinical trials conducted since formation gsk includes clinical trials companies end research proposals submitted access data gsk trials already given research teams access detailed trial datagsk responsible business supplement behaviour rigorous patient consumer safety patient safety paramount understanding risks global risk register helps research combating risks counterfeit products prescribing taking medicine teams keep track risks quality safety company immune threat throughout development health workers patients need know standards risks often identified counterfeit products impossible testing manufacturing associated risks well benefits regular audits trials eliminate risk completely committed extensive controls place designed conducted third party minimise patients consumers receive products detect evaluate communicate benefits behalf performed audits authentic medicines healthcare products risks potential safety concerns see data summary collaborate multiple stakeholders products effectively tackle public health threat ensuring quality manufacturing supply support global fight fakes research teams assess benefitrisk produced million doses campaign aims raise awareness profile medicine throughout development vaccines around two billion packs medicines dangers counterfeit medicines use results reviewed five billion packs consumer global safety board makes decisions healthcare products manufacturing cases reported product safety issues chaired chief sites around world confirmed counterfeit gsk products medical officer composed senior countries raid actions conducted committed meeting highest commitment continue ensure physicians scientists board oversees targets involved manufacture standards stringent quality control interests safety patients consumers policies controls product safety best distribution andor sale counterfeit gsk quality assurance processes medicines paramount importance way practices also shared across business products resulted arrests vaccines manufactured according design undertake clinical trials internal risk advisory panel good manufacturing practice cgmp continued support interpol along product quality assurance monitoring also collaborate industry peers regulators regulations internal quality management pharmaceutical companies reporting adverse events ongoing healthcare providers enhance detection system regulatory threeyear industry initiative combat product usage monitoring understanding prevention inspections pharmaceutical supply sites counterfeiting brand generic adverse effects known pharmacovigilance vast majority concluded satisfactory drugs initiative targets organised crimes gsk awarded bioit world outcomes working regulators involvement manufacture distribution best practices award collaboration bring inspections remaining concerns sale counterfeit pharmaceuticals well progress overview progressing well informatics company epidemico monitor publicly acceptable conclusion vaccines raising public awareness dangers available information social media gain business regulatory inspections purchasing counterfeit drugs particularly insights adverse effects medicines consumer healthcare supply sites purchased online satisfactory outcomes putting patient safety first clinical research extended supply chain serialisation trials conducted accordance along internal controls supplier programme fingerprint across packaging international conference harmonisations requirements also designed ensure lines manufacturing sites good clinical practice guidelines consistent high quality safety programme applies unique serial fingerprints employees involved trials trained production products endtoend many products logs good clinical practice trials start approach safeguards patient consumer governmentmanaged database products independent ethics committee reviews safety helps us deliver highest quality verified point supply chain protocols committee prevent trial products improve safety performance conducted reduce wastegsk responsible business supplement behaviour minimising animal testing working new medicines vaccines undergo careful developing alternatives animal studies checks assess effects human reduce need vivo within change animal use vs index year alternatives using animals body animal studies provide vital information living body animal studies researchers need research ensuring obtained alternative methods nonanimal testing methods model form legally required test medicines function living human tissue animals used vaccines animals starting clinical sponsored development computer required trials protect patients unexpected model predict drug concentration humans potentially lifethreatening adverse effects based vitro outside body data also required use animals releasing also sponsored collaboration uses vaccines amoeba replace rodents certain studies apply established rs approach partnering university college london replace animal research possible explore human cells tissues could reduce number animals needed refine techniques improve animal welfare scientific used enable vitro testing potential n animals used within gsk facilities replacement animal studies also n animals used contractors behalf gsk peer review challenges need animal ongoing experimental projects european studies integrating nonanimal animal figures normalised first year data commitment rigorously challenge need bioinformatics institute sanger centre formation gsk testing approaches ensuring studies animal studies work minimise area gsk scientists leading due variation methods collection collation relevant reproducible animal numbers gsk novartis animal impact animal welfare investing crosspharmaceutical group partnered numbers former novartis sites included within development alternative studies sharing used fewer animals national institute health usa design animal number figures reporting cycle resolved next reporting cycle animalbased data continuation downward trend test artificial organ systems called organ nine years tied changes projects chips drug safety testing programs commitment rs ensuring animal welfare sponsor two projects national animals used rodents office animal welfare ethics centre replacement refinement progress overview progressing well strategy led chief veterinary medicine reduction animals research ncrs oversees humane responsible use create vitro system replicates ability animals teams trained motivated human skins ability metabolise substances prioritise animal welfare recognise explore nonanimal methods assessing innovative ideas animal welfare awards safety new gene therapy treatments standards processes ensure animal increasingly use vitro methods welfare apply animal studies conducted within quality control vaccines one biggest gsk contractors suppliers requirements animal testing sector work contractors fail support european commissions implement recommendations show partnership accelerate acceptance commitment improve alternatives animal use regulatory testing animal programmes care welfare treatment animals gsk former novartis vaccines consumer healthcare currently integratedgsk responsible business supplement behaviour promoting human rights working address gsk signatory un global compact human rights steering group provides activities embargoed countries sets key principles business companywide direction oversight help operating countries targeted sanction human rights impacts human rights committed upholding ensure meet commitments human laws cuba iran north korea part commitment universal declaration human rights rights set human rights statement sudan syria raises concerns core labour standards set steering group focused managing stakeholders represents challenges support un guiding international labour organization thirdparty risk particular emphasis risks business although sanctions principles business public policy statement working third lifted iran others remain force un guiding principles business parties labour rights health safety comply disclosure requirements human rights human rights set clear expectation steering group also addressed gsks position iran threat reduction syria human business respect human rights undertook living wage ensuring childrens rights rights act independent thirdparty assessment integral part consideration human help us understand potential human rights believe people access rights broadly transparency impacts associated business essential medicines regardless countrys requirements modern slavery act identified seven priority areas access health regime wherever people need medicines care air quality impact relating propellants gsk living wage accredited employer vaccines aim supply including clinical trial standards employment practices uk although already pay uk essential medicines sanctioned countries patient safety product counterfeiting use employees living wage compliance applicable sanctions thirdparty suppliers accreditation extended commitment export controls appropriate work commitment address un guiding efforts areas outlined thirdparty contracted employees uk partnership make gsk medicines principles business human relevant sections report since vaccines available particular rights across operations particular focus improving alternatives exist supply supranational supplier relationships companywide risk management controls groups like unicef direct government use thirdparty suppliers privacy data security identified key risks area introduced employees suppliers must ensure comprehensive new programme strengthen personal data collected used processed progress overview track management risks find transferred stored appropriately securely programme line global privacy principles legal see requirements see website summary binding corporate rules safeguarding personally identifiable informationgsk responsible business supplement behaviour ensuring ethical interactions committed political advocacy gsk make corporate political european health advisory board hab brings interact regularly governments contributions sponsor political patient group leaders together gsk give engaging ethically policymakers stakeholders advocate meetings anywhere around world us insights key policies initiatives issues transparently political policies encourage innovation promote employees financially support political groups reflect best interests patients efficient management healthcare spending individual candidates political action hab discussed patient involvement research key stakeholders give patients support need committees pacs federal election changes making work campaign act gsk employees healthcare professionals see employees involved lobbying activities pac contributed state federal must follow relevant requirements set patient advocacy leaders summits candidates funds contributed code conduct also expect pals bring together diverse group federal candidates funds thirdparty policy groups engage patient advocacy leaders gsk employees contributed candidates state offices behalf share values build understanding develop skills comprehensive criteria guide selection find see gsks public policy identify ways collaborate appropriately groups standard operating position political advocacy pals events held germany procedure managing public policy groups japan slovenia switzerland usa engaging patient advocacy groups commitment demonstrate gsk reflects criteria also train relevant focusing critical role patient advocacy engage support patient interactions patient advocacy groups employees related global policy organisations gain insights enable us gsk founding member patient political stakeholders conducted grants donations develop products advocate policies focused medicines development initiative appropriately ethically transparently gsk ranked top three better meet patient needs bringing together stakeholders transparent ftse companies including patient organisations research new global standard interactions transparency international corporate development work comprehensive patient organisations outlines work political engagement index index assesses systematic approach patient involvement progress overview progressing well patient groups collaborate projects open companies political clinical development gather insights ethically transparently engagement quality reporting funding gsk exceed political activities governed patient groups annual revenue managed implemented respect independence seek register lobbying costs eu transparency endorsement promote medicines register us federal lobbying register publish information financial cost representing interests nonfinancial support provide eu institutions range patient organisations website us federal lobbying activities activities include running advocacy offices brussels washington dc well cost consulting travel includes running advocacy office brussels salaries trade association membership fees representation consulting costs activities increase year year declared figures higher published new rules guidelines also publicly list membership trade eu transparency register gsk followed european trade associations efpia interpretation guidance implementing newly industry associations may lobby indirectly revised guidelines behalf see website full list see us federal lobbying register figure covers costs salaries benefits employees registered lobby us government lobbying consultant costs research running government affairs office washington dc support staff also includes proportion gsks trade association fees associated federal lobbying due reporting error amount spent us federal lobbying activities incorrectly stated responsible business supplement correct figure stated heregsk responsible business supplement behaviour approach tax understand responsibility pay relationship tax authorities figure given country appropriate amount tax fully support seek maintain open positive relationships given year viewed isolation may accurately corporation tax efforts ensure companies appropriately governments tax authorities worldwide represent full picture amounts reported last years paid transparent tax affairs managed welcome constructive debate taxation core financial results billion corporation tax globally policy appropriate means group representative gsks tax position time uk paid billion since substantial business employment entered arrangements nearly global total presence many countries around world transfer pricing continuous audit programmes advance uk net sales global net sales pay significant amount tax including line current oecd guidelines base pricing agreements agreements provide corporation business taxes well transfer pricing policy arms length group paid corporate longterm certainty tax authorities tax associated employees principle support transfer prices income tax gsk tax treatment gsks business time responsibility economic analysis reports worldwide profits shareholders financially efficient international tax framework nature operations means representing cash tax rate deliver sustainable tax rate support oecd g principle intellectual property rd manufacturing corresponding tax paid throughout supply chain operations centred number key accounting tax charge profits part approach look align commensurate profit making locations consequence investment strategies countries activity takes place base erosion crossborder supply routes necessary already substantial economic activity taxes profit shifting beps project constructive ensure supplies medicines numerous government policies promote tax well corporation tax paid modernisation principle addressing end markets complex regimes attractive business additional business taxes anomalies grown time investment uk patent box tax havens another tax collected eg believe multinational economic engage artificial tax arrangements employee income tax pay considerable amount tax uk activity many countries around world without business commercial significant proportion global basic principle means profits substance substantial local business corporate functions rd manufacturing arise taxed different locations presence vast majority territories bn activities located includes country country reporting operate whether business corporation tax profits generated well support implementation oecds offices sales force manufacturing rd facilities indirect tax employment taxes although recommendations countrybycountry local distribution products precise amounts fluctuate year year corporation tax paid reporting cbcr key success contribute economic development create years governance beps project aligned core values shared value region business robust internal policies processes transparency integrity support training compliance programmes ensure exchange cbcr data tax authorities alignment across business data validated existing information meet tax obligations audit risk held taxpayers support ability committee board responsible ensure multinational groups pay right amount approving tax policies risk management tax however tax payments vary year year investments made returns generated long term investment cyclegsk responsible business supplement behaviour working third parties aim build strong suppliers third parties including large supplier base need focus also expect suppliers third parties agents distributors affiliate companies effort working highest comply gsks quality safety standards relationships third equity stake help us develop risk noncompliance standards global manufacturing supply team continue parties support distribute medicines vaccines products responsible business following review manage regularly assess performance patients consumers need suppliers identified around suppliers support manufacturing business share considered highrisk based country specifically quality ethical environmental every year spend billions pounds tens values operate type product service health safety ehs management systems thousands suppliers wide range goods provide value contract also assessed suppliers services essential strengthen identified highrisk distributors line quality management system relationships suppliers third parties conducting assessments focusing four key audited suppliers specifically ehs critical business work risks antibribery corruption labour rights share values operate responsible completion audits identify areas promotional activities information protection ethical manner support commitment improvement work suppliers develop increased use preferred suppliers identified highrisk improvement plans check plan suppliers must undergo assessment form implemented within agreed time frame extensive questionnaire environment significant concern identified may suspend also collaborating suppliers manage labour human rights fair business practices terminate work existing supplier commitment seek work third environmental impact creating products sustainable procurement manage decide work potential new supplier parties share commitment high medicines example supplier risks supply chain responses ethical standards operate responsible innovation forum see supporting suppliers assessed external experts way performance gaps identified managing thirdparty risk suppliers must provide supporting evidence responsibility support suppliers appropriate commit working addition meeting gsks antibribery demonstrate appropriate policies paying time put place third party improve performance corruption labour rights standards management systems place exception standard payment terms small medium sized companies relevant expect third parties based risk assessment uk small diverse suppliers usa comply standards quality safety questionnaire scores additional due diligence number initiatives underway health safety environment progress overview track may required including detailed review continuously improve experience principles clearly set contract clauses monitoring activities suppliers work us public statement working third parties highest risk suppliers onsite audits introduced comprehensive new part commitment diversity time strengthening management programme strengthen management inclusion support suppliers run groups risk existing suppliers part risk supply chain focus underrepresented supply chain global deployment programme programme ensure third parties owned women minorities ensure country capabilities risk assessed gsk principles disabled veterans supplier diversity processes place assess thirdparty risks contracts amended necessary programmes engage mentor small new suppliers end diverse businesses supply chain help identify potential areas growth usa procurement spend small businesses gsk responsible business supplement people pulse volunteer partnership employees use professional skills create sustainable change nonprofit partners communities servegsk responsible business supplement people approach invest people ensure longterm highlights sustainability business order help us engagement inclusion tackle biggest global health challenges employees signed uk governments need talented motivated resilient workforce workforce took part global disability confident campaign part employee survey commitment remove barriers employment aim create working environment employees feel valued respected opportunities disabled people empowered inspired listening read supporting people particularly important year significant changes business many disabled people find read take progressive approach locked employment employee health going beyond conventional initiatives disability confident health safety remains fundamental healthy workforce employers like gsk setting bar focus energy resilience really important people taken part provide unprecedented access preventive one global energy resilience mark atkinson health services programmes since ceo scope help employees learn new skills talent development gain new experiences support personal recruited apprentices read ambitions drive business forward graduates postgraduates volunteering combining development opportunities since employees countries volunteering example pulse read providing preventive healthcare provided million worth skilled programme benefits people business addition healthcare benefits services nonprofit partners nonprofit partners established markets global partnership pulse volunteering programme prevention programme provides early talent community gifted diverse representing future dynamic preventive healthcare read employees family members organisation business benefits diverse workforce clear fresh ideas varied experiences promoting better decision making developing leaders reflect understand markets serve developing local talent mentoring aspiring female leaders read becoming disability confidentgsk responsible business supplement people focus inspiring next generation scientists uk alone need million aim build experience new scientists engineers solve future uk creating global stem education challenges including biggest health programmes give employees tools challenges tomorrow researchled need inspire foster next healthcare company gsk playing leading generation scientists engineers worldwide role inspiring young people get science gsk offers range career opportunities technology engineering maths stem stem areas ranging summer internships well providing range career opportunities apprenticeships graduate postgraduate science education early talent team along programmes apprenticeship programme stem ambassadors across uk offers school college leavers opportunity engage young people demonstrating realworld join company variety roles science engineering schools manage finance laboratory science graduate apprenticeship programmes engineering apprentices learn onthejob become valued members team rhiannon lowe heads team progress working towards nationally recognised ambassadors volunteer gsk employees qualifications ultimately transition site ware hertfordshire part permanent role programme since began alongside job investigator investigative safety scheme grown steadily uk drug metabolism focuses ambition continually expand diseases developing world gene therapy programme new geographies helping nurture new generation talent team put expertise practice adding diversity business inspire people ages go schools demonstrate scientific experiments host visits gsk labs students given opportunity get involved science connects directly work real world rhiannon encourages girls particular pursue subjects young age women represent stem jobs uk young told one teachers study drama always enjoyed sciences maths ended completing phd virology immunology parttime whilst gsk said stem ambassadors across ukgsk responsible business supplement people developing people inspiring healthy workplaces attract retain need motivated talented people performance right skills knowledge help us tackle global performance system listening employees best people foster worlds important health challenges employees set objectives support employees ever resilient healthy people strategy focuses four areas development business strategy shared views employee survey talent leadership performance engagement underpinned set clear expectations response rate workforce create emphasise results people achieve providing us valuable feedback talent inspiring place work way achieve line values number graduates postgraduates results survey tell us employees joining programmes increasing engagement clear accountabilities feel recruited graduates postgraduates help people understand empowered perform roles onto future leaders esprit programmes contribute success business right way globally exceeding target also provide regular updates mission also encouraged marked welcomed apprentices uk strategy progress live broadcasts improvement managers supporting women across number disciplines messages ceo members worklife balance communicate locations looking expand corporate executive team listening reasons important changes apprenticeship programme people also critical success external benchmark geographies people record workforce commitment continue create working took part employee survey provided however results also showed engagement environment inspires people grow leadership valuable feedback help us become better scores whilst remaining positive fallen perform healthy resilient way provide employees levels skills employer see box thank staff sharing given amount significant change need advance careers put views donated save children gsk unexpected particular emphasis leadership development person completed survey support succession planning business putting place strategy progress overview progressing well line leaders completed welcomed novartis employees improve engagement track leadership programmes help transition gsk clear regular communication critical progress range measures managerial roles since trained whilst onboarding new colleagues including active use interim people globally act coaches values expectations performance system surveys help others fulfil leadership potential local employee practices programmes major reshaping global pharmaceuticals launched enterprise talent business occurring time placed initiative strengthen leadership pipeline equal focus supporting employees leaving initiative accelerates development company outplacement service providing leaders potential aspiration effective coaching assistance consult move executive roles within next employees representatives including four eight years participants sponsored unions work councils changes business leadership team attend business might affect events designed develop enterprise external perspectivesgsk responsible business supplement people developing people inspiring healthy workplaces continued protecting people global business operating building employee resilience providing preventive healthcare protecting health safety people markets serious incidents occur august business health starts complement employee healthcare important focus refreshed one employees tragically died people end benefits established markets simplified standards help everyone gsk boiler explosion site rixensaart belgium assessed health needs employees partnership prevention pp programme aims understand need safeguard addition supporting belgian authorities sites using insights provide employees families people business environment investigations taking steps assessments target unprecedented access preventive healthcare global health wellbeing strategy check operations every boiler across gsk health needs identified across business services little cost implementation also reviewed setting plan ensure design employee health plans coming prioritised regions access october sales employee india every gsk employee access consistent year raise awareness among leaders preventive services unavailable limited travelling business sadly died comprehensive health service continue local health programmes particularly developing markets motorcycle collided another vehicle recognised leader health help people achieve healthy lifestyle services including immunisations wellbeing may gsk august explosion nearby chemical working major sites cancer screenings recommended multinational healthy workplace award warehouse damaged several buildings site countries employees world health organization available global centre healthy workplaces tianjin china two employees suffered ensure core programmes available employees family members minor injuries allowing staff return working hard address road exercise classes discounted fitness countries places us halfway towards checked structural integrity site safety significant risk employees centres labelled healthy food options nutrition target implement pp globally monitored air quality toxic chemicals particularly emerging markets last year education support quit smoking since employees surveyed approximately six launched driver safety programme india workforce taken part months pp implemented country help employees protect one global energy resilience reportable injury illness rate results shown almost third families programme combines online programmes feedback indicates employees family member used learning practical road safety activities focus energy resilience helping services satisfaction rate driver motorcyclists rolled employees improve personal resilience bangladesh cambodia indonesia wellbeing time took part countries turkey pp pakistan vietnam employee survey agreed place longer period time seen sufficient energy invest things incremental increases awareness uptake seen steady reduction matter work life services maintaining high satisfaction reportable injury illness rate past years slight increase occurred also offer counselling confidential programme piloted ecuador ghana mainly due large number employee assistance programme eap support nigeria romania since semicircular lipoatrophy cases treatable employees dealing personal health wellbeing expanded middle east turkey condition associated localised pressure professional issues employees africa latin america early office furniture identified offices access service continue launch pp india sri lanka bangladesh n reportable injury illness rate brazil taken comprehensive steps per hours worked work overcome cultural barriers could russia members commonwealth support impacted prevent recurrence make people reluctant use service independent statesgsk responsible business supplement people promoting inclusion diversity diverse knowledge value diversity aim offer inclusive employees gender december partnered uk working environment welcomes people governments disability confident campaign perspectives experiences male female total walks life survey raise disability awareness across company working styles proportion employees agreeing work remove barriers increase understanding organisation diverse perspectives total ensure people disabilities global workforce support valued rose five points right opportunities women management positions business help us gender diversity membership business disability better meet needs aim improve gender balance international social enterprise involving encouraging women join business svpvp several global standards measure businesses patients consumers develop leaders women director disability performance represented recruits future manager around world cultural ethnic diversity leaders programme management total six nationalities represented corporate corporate executive team disability executive team board people board enhancing attractiveness accessibility employ emerging markets asia pacific accelerating difference programme business people disabilities japan represent workforce supports development high performing priority gsk global disability council aim attract develop local talent across female leaders help advance gdc identified range opportunities markets partnering universities careers take senior roles increase gsks disability confidence offering opportunities within business female managers began making facilities technology particular focus africa strategy build programme includes individual group accessible addressing culture capability across continent creation commitment continue promote inclusion coaching sessions internal external employee attitudes disability new regional headquarters singapore diversity globally gsk coaches supported line managers set new disability confidence also provides opportunity attract senior sponsors group dialogue sessions network provide forum employees develop talent asia provide platform male female find accessibility raise leaders discuss career progression build strong pipeline important progress overview track awareness local initiatives also gsk share experiences well future leaders represent diverse markets launched online accessibility portal prompting actions address genderrelated serve stay close patient needs around enables employees uk request issues nearly female participants world recruited people additional support adjustments since achieved promotion countries future leaders working environment looking roll taken responsibility role graduate programme service countries womens leadership initiative one uk business welcomed students employee resource groups supports culture learning disabilities transition inclusion aims empower women education employment project search achieve potential students completed members new groups launching placements gsk since began africa europe singapore employment discussions st december taking place explore feasibility setting project search gsk locationsgsk responsible business supplement people community volunteering create change people develop pulse volunteer partnership also encourage employees around world employees lend professional skills support local communities offering one paid pulse volunteer partnership skills support nonprofit partners help meet healthcare day year volunteer orange pulse volunteer partnership communities around challenges home abroad working day programme people volunteered employees use professional skills partners fulltime three six months time world supporting create sustainable change nonprofit world volunteering people challenged think differently recreation camp young girls india packing partners communities serve time expertise develop leadership skills bring new school supplies children usa many avinash mohanty product group experiences fresh ideas back gsk employees use orange days activities manager gsk india worked supporting stem education see case study six years since launched pulse clinton health access initiative inc chai uk one scientists employees contributed million abuja nigeria develop comprehensive worked project develop natural history worth skilled services nonprofit strategy increase treatment access museums molecular laboratory facilities best suit partners countries pulse children pneumonia conducting current future demands opportunities volunteers come countries baseline assessments current practices half volunteers continued leverage global infrastructure key issues interviewed key outside uk usa ambassadors promote volunteering gsk stakeholders formulated plan programme first started annual volunteer awareness week direct impact policy resource commitment extend volunteering total activities carried mobilisation market shaping opportunities bring positive change pulse programme aims create across gsk sites countries including reports assignment exceeded communities global health positive sustainable change partner town hall serbia farmers market finland expectations increased awareness providing individual development organisations communities serve measure footprint day colombia importance patientfocused survey nonprofit partners six months information stands dubai uganda inspired find innovative volunteers completed insightful solutions impact lives assignments partners said gsk invited founding partner progress overview progressing well volunteers contribution impact global collaboration time clinton health access lasting impact un led private sector aims mobilise initiative inc helped increase corporate volunteers contribute global geographical reach partnerships volunteers also bringing back valuable goals sustainable development key stakeholders india skills support development collaboration nigerian government benefit business volunteers highperforming staff disease national interest say something different gsk return line managers member located us six valuable experience transfer directly role gsk colleagues agree experience months entirely paid bringing helped develop skills performance new skills experience since partnership save children began gsk employees raised organisation valuable also go website hear million increased leads much deeper partnership people experiences million matched funding pulse volunteers gsk find save children organisations read pulse impact report partnership x website simon wright head child survival save childrengsk responsible business supplement planet announced investment million enhance antibiotic manufacturing facility quality road singaporegsk responsible business supplement planet approach major global environmental challenges like climate highlights change deforestation exacerbating health carbon trust water issues undermining efforts overcome gsk still pharmaceutical company reduction water usage since inequalities around world consequences hold carbon trusts carbon standard hitting water target year early current future generations likely cutting carbon emissions water severe poorest particularly vulnerable carbon standard reducing water use across new un global goals sustainable operations globally reduced direct carbon emissions development draw clear links health scope since saving environment million tonnes co e five years changing environment lead higher levels read air pollution spread disease vectors food insecurity undernutrition displacement reducing water year year supplier engagement forced migration socioeconomic stresses contribute health issues read sustainable supplier programme read award best supplier engagement global healthcare company ethical corporation responsible contribute tackling effects waste business awards environmental change part work cdp results deliver health causes less waste produced targeting carbon neutral value chain score climate change disclosure manufacturing rd sites read ambitious goals reduce carbon water b performance cdps ftse achieved zero waste landfill waste meantime last five years climate disclosure leadership index made significant progress feedback ethical corporation judges work suppliers gsk also making contribution environmental challenges sharing knowledge comprehensive programme focuses resources participation reducing scope carbon emissions read un caring climate initiative un ceo using ecodesk evaluation supplier water mandate businessled movement exchanging workshops well advance water stewardship sanitation carbon footprint supplier awards gsk solved reduced value chain carbon every problem making good footprint products shipped progress areas hold average versus influence judges appreciated gsks candid approachgsk responsible business supplement planet focus horlicks takes green leap india horlicks one bestknown brands also installed effluent treatment used nutritional supplement india plants rainwater harvesting systems provides essential vitamins minerals enable water reused disposed growing children safely cutting water use helping replenish groundwater restore discovered lifecycle local water sources analysis horlicks second largest carbon footprint products one reason identified huge three horlicks factories opportunity reduced india nabha rajahmundry sonepat powered coal carbon emissions sonepat investing million project green tonnes leap reduce carbon emissions water use three horlicks factories example continue increase amount waste satyaprakash punia biomass buy replace coal fuel utilities site energy manager sonepat india boilers constructing new mw combined heat power plant rajahmundry also fuelled waste biomass plant improve efficiency capturing heat power generation would otherwise wasted sonepat installing photovoltaic cells generate mw power solar energy investing efficient led lighting across three sites cut energy use since project began april cut carbon emissions investment improve carbon water management three horlicks factoriesgsk responsible business supplement planet understanding value chain carbon footprint raw materials gsks operations logistics use products disposal sourcing raw materials impacts delivering medicines vaccines patients consumers using disposal products gsk buys companies labs factories offices consumer health products products gsk patients consumers across globe tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum use metered energy tonnes coe per annum tonnes coe per annum dose inhalers hfa process use tonnes coe per annum emissions tonnes coe per annum products business travel tonnes coe per annum sales force tonnes coe per annum total estimated emissions estimated tonnes coe per annum data excludes former novartis sitesgsk responsible business supplement planet aiming carbon neutral working reduce performance therefore reduced value chain raw materials reduced operational emissions carbon footprint products shipped engaging suppliers crucial reduce emissions entire scope million average versus emissions raw materials approach value chain extending tonnes coe less recognised ethical corporation continued growth sales cumulative saving million tonnes coe responsible business awards founded access products ventolin propellantbased inhalers emit five years achieved reductions data collection collaboration recognition greenhouse gases administration people need continued focus energy efficiency use ecodesk online platform gather medication patients impacting emissions investment renewable energy data carbon water waste around scope continue research solutions provides around total energy use suppliers representing approximately issue including changing way million raw materials begun decouple environmental manufacture reduce amount propellant impacts business growth increased used maintaining efficacy patients around suppliers using online access medicines volume tackling emissions use medication supplier exchange platform share best medicines consumer health products remains challenge impacts ability practices worked directly vaccines sent factories meet target cut absolute emissions across five suppliers identify ways reduce higher time value chain value chain carbon emissions energy carbon footprint grown vs supplier environmental sustainability award commitment reduce overall carbon went flavourings supplier firmenich sa footprint vs comprehensive environmental programme carbon neutral value chain scope ghg emission scope ghg emission engagement suppliers tonnes coe tonnes coe progress overview work target target gas fuel purchased materials electricity steam product logistics propellant emissions manufacture inhalers business travel air sales force travel propellant emissions use inhalers emissions use products reduced value chain carbon footprint excluding biogenic emissions year according disposal products products shipped average current guidance accounts decrease emissions estimated data data excludes former novartis sites versus gsk responsible business supplement planet aiming carbon neutral continued operations logistics disposal investing renewable energy partnering logistics providers biggest carbon impact customer deforestation infrastructure converting lowemission reduce emissions transportation disposal products also comes deforestation major contributor climate fuels improving energy efficiency cut products account around inhalers often small amount change taking steps ensure emissions operations wind carbon footprint example encouraged propellant greenhouse gases left raw materials woodbased packaging turbine installed site cork ireland suppliers invest specialised trailers use since encouraged materials palm oil sourced responsibly generating sites electricity support storage two different uk patients return used working rainforest delivered savings million temperatures products requiring different inhalers pharmacies sent alliance map risk packaging supply tonnes co e levels refrigeration transported back us recycled complete chain used analysis support together enabled us take cycle scheme also working announced investment new sourcing standard packaging vehicles road cut carbon healthcare trusts across uk combine million enhance antibiotic regularly assess suppliers ensure emissions tonnes coe per year health environmental messages manufacturing facility quality road meet standard also using route planning tool projects like dont waste breath singapore addition million paper packaging materials used enables vehicles reduce journey times grampian region breathe better waste less announced developed operations sourced responsibly make trips efficient reducing brighton support patients get roll process manufacture increase achieved carbon emissions inhalers reducing need antibiotic amoxicillin using enzyme technology sourcing materials suppliers emergency care cutting waste increase production paper mills certified reduce sites carbon emissions forest stewardship council moving away using chemical process biodiversity goal source least paper also eliminate chlorinated solvents biological materials including genetic packaging gsk branded products organic waste resources commonly used according standard million investment combined heat tonnes co e saved annually development new medicines palm oil production damaging power chp boiler stevenage uk vaccines gsk directly involved effects important rainforest areas expected save million year energy bioprospecting although source purchased greenpalm certificates patient use costs reduce sites carbon emissions materials derived natural covering tonnes palm oil worked carbon trust quantify brings total number chp products uphold nagoya protocol use make horlicks uk carbon footprints biggestselling boilers taking care biological resources certify supporting production products different stages value chain obtained legitimately used sustainable palm oil every tonne patient use metered dose inhalers way intended palm oil buy equivalent mass carbonintensive activity across whole sustainable palm oil produced portfolio aerosol propellant used administer medication powerful gsk minimum conditions virgin wood fibre specify material must legal origin must harvested greenhouse gas continuing explore violation traditional civil rights high conservation ways reduce impacts extending value forests forests converted plantations nonforest use access essential medicationgsk responsible business supplement planet reducing water impact better understanding performance operations met target cut water use across gsk laboratories manufacturing sites operational water use water use across operations compared offices used million water million value chain focus year early reduced around total value chain water investment watersaving footprint making major investments efforts initiatives past five years helped reduce across sites example make biggest difference us achieve reductions targeting sites identified several areas nairobi site highest water use located kenya collect reuse water regions water scarcity installed efficient system heat water sites water meet commitment working consumption decreased experts ngos understand best reduce water impact across entire value consumer use chain combined data wwf water consumers patients need water use risk filter four focus areas water scarcity many products making cup local water quality health social risks horlicks brushing teeth help swallow target regulatory reputational risks identify tablets estimate consumer use commitment reduce water hotspots high water impact many accounts water footprint impact across value chain projects emerged assessment water used cleaning teeth vs continued promote turn tap raw materials campaign sensodyne uk website around water used across value printing logo sensodyne pronamel chain estimated million year progress overview progressing well toothpaste encourage people leave producing raw materials much water running brushing teeth agricultural produce milk sugars eggs consumer use products potentially partnered energy resources alter water quality well quantity institute teri sustainable development ngo pharmaceutical products use always india assess help reduce completely absorbed broken water impact rural indian communities body residues find way supply us wheat barley milk used environment particularly water courses manufacture horlicks piloted medicines excreted disposed approach direct suppliers assess environmental risk associated extended work patients use products help ensure supply chain suppliers rural community potential concentrations environment level identified projects address exceed safe levels includes testing water conservation rainwater harvesting waste active pharmaceutical ingredients water treatment groundwater recharge ecotoxic properties since rehabilitation water bodies investigating published data summaries environmental options implement research risk assessments many products data excludes former novartis sitesgsk responsible business supplement planet reducing waste changing performance singapore quality road site partnered packaging continued make progress towards national university singapore also want reduce waste beyond manufacturing halve commitment cutting operational install onsite treatment facility hazardous operations work suppliers amount operational waste hazardous nonhazardous waste uses photooxidation break buying less material sharing best last five years potentially harmful chemicals organic practices sustainability supplier waste generate substances safely released exchange see focused investment infrastructure technology shifting environment process cut packaging asking suppliers submit ideas yielded results produced tonnes waste saved tonnes reduce amount paper packaging perceptions see waste tonnes waste less coe eliminating need needed consumer healthcare products previous year tonnes representing incineration third parties potential resource total waste sent landfill tonnes waste quality road reduction tonnes compared jurong sites also singapore used fuel operational waste landfill lower tonnes jurongs steam boiler generating million kwh thousand tonnes operations energy cutting sites energy encourage sites think differently costs waste view resource instead discarded reused recycled used generate energy turned corner operational waste generated half manufacturing thousand tonnes rd sites achieved zero waste landfill commitment reduce end sites sent operational waste vs waste landfill sharing best practice help sites learn others achievements progress overview track work towards goal example site east durham usa building insights shared dungarvan site ireland install machine recycle fibre drums used packaging storage transport saving us year many sites introducing innovative solutions commitment cut waste streams facility sainte foy canada sending egg waste vaccine production tonnes sold compost secured regulatory approval st louis site usa also sending manufacturing waste composting instead landfill data excludes former novartis sitesgsk responsible business supplement data summary health notes better access medicines vaccines number doses rotarix vaccine donated gavi million cumulative value gsk medicine vaccines prescribed us patient assistance programme million usd number patients reached us patient assistance programme community investment total global community investment million strengthening healthcare systems reinvestment ldcs million healthcare workers partners trained cumulative number people reached reinvestment programme million cumulative neglected tropical diseases albendazole tablets help lf elimination million albendazole tablets help treat intestinal worms million total albendazole tablet donation total albendazole tablet donation since million eradicating polio number doses oral polio vaccine delivered global polio eradication initiative million access antiretroviral treatment hiv number countries viiv healthcare access programmes operate number royaltyfree voluntary licenses available viiv healthcare products behaviour notes compliance employees disciplined policy violations employees dismissed agreed leave company voluntarily documented warnings total number marketing promotional activity violations breaches external codes number contacts made speak channels clinical trial data cumulative publicly available trial result summaries number studies clinical study reports posted register number trials listed data available request number research teams approved requests access gsk trial data gsk responsible business supplement data summary behaviour notes clinical research clinical quality assurance assessments audits investigator sites conducting gsksponsored trials audits gsk processes audits contract research organisations carry clinical trials behalf audits gsk local operating companies involved clinical trial activities investigations suspected irregularities inspections gsk sites regulatory authorities anticounterfeiting number reported cases confirmed counterfeits number raids law enforcement authorities number arrests law enforcement authorities ensuring quality manufacturing supply number regulatory inspections pharmaceutical business number regulatory inspections vaccines business number regulatory inspections consumer healthcare business people notes number fatalities reportable incidents lost time lost time reportable injury illness rate per hours worked reportable incidents without lost time reportable injury illness rate per hours worked talent leadership development total number coaching assignments number graduates recruited number postgraduates recruited number apprentices recruited inclusion diversity percentage women management total percentage employees emerging markets asiapacific japan volunteering number employees completing pulse gsk responsible business supplement data summary planet data baseline notes carbon scope ghg emissions tonnes coe gas fuel electricity steam propellant emissions manufacture inhalers sales force travel emissions total scope ghg emissions tonnes coe purchased materials estimated data product logistics business travel air propellant emissions use inhalers use products estimated data disposal products estimated data total water water use operations million cubic metres waste total waste generated thousand tonnes waste landfill thousand tonnes compliance internal audits number environmental fines environmental remediation spend million detailed breakdown environmental fines available responsible business supplement fines mostly due discovery waste tank upper merrion site comply local regulations plus fine paid hamilton site failure submit risk management plan storage use chloroform take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies usedgsk responsible business supplement read online publish detail many topics report website health behaviour people planet clinical trials developing world gsk antibribery corruption hazardous chemical management climate change handbook developing world vaccine production gsk reach genetically modified microorganisms technology transfer gsk antibribery corruption employee volunteering ozone depletion metereddose guidelines third parties ip access medicines inhalers asthma gsk future leaders programme developing countries direct consumer marketing pharmaceuticals environment prescription medicines gsk careers site pandemic preparedness developing use ozone depleting substances countries cloning technologies stem ancillary plant equipment cell research technology transfer capacity building green chemistry greener processes developing countries disclosure clinical trial information labs working together health mothers care welfare treatment animals detailed environment data table children role transgenic animals assurance statement gsk briefing noncommunicable biomedical research diseases developing world gsk response assurance statement use nonhuman primates nhps gsk position statement post discovery development medicines development agenda vaccines tiered pricing vaccines counterfeiting healthcare products product donations pharmacovigilance noncommunicable diseases criteria working public policy groups code conduct clinical trials developing worldgsk responsible business supplement summary assurance statement bureau veritas summary independent opinion recommendations statement independence impartiality assurance statement based assurance work carried competence reporting bureau veritas uk limited engaged evidence presented bureau veritas independent professional report performance annually gsk plc provide independent assurance per scope work nothing came services company specialises quality report part commitment environment health safety ehs attention suggest factual information environment health safety social open transparent performance data objective performance metrics data contained within accountability years history business activities responsible business bureau veritas work express opinion gsks ehs performance data assurance team extensive experience also covered annual report accuracy reliability ehs environmental social ethical health provide fair summary ehsrelated activities data coverage data provide summary findings safety information systems processes performance data report relates gsks bureau veritas code ethics ensures staff full assurance statement found contain performance metrics information members avoid conflict interest maintain global operations calendar year includes details scope work based established collection high ethical standards business activities except otherwise stated methodology findings recommendations collation processes deemed data environment health improvement free significant error omission bias gsks response assurance safety sections independently pleased bureau veritas findings verified bureau veritas brand names summary scope methodology quality data evidenced site gsks established processes managing appearing italics throughout report assessment performance data contained consolidated level seen based ehs data committed continue trade marks either owned andor within ehs data table associated date recently implemented improving ultimate goal providing licensed gsk associated companies data management processes involved data management system ehs central accurate ehs data public detailed review integrity selected supporting processes guidance website continue work reporting standards datasets aggregation checking index global reporting processes corporate level well implementation ehs central towards improving data accuracy initiative guidelines shows elements sampling data back source five gsk comprehensive effective improving emphasis incorporating recommendations covered report signatory sites sites chosen represent submissions data accuracy provided bureau veritas un global compact publish significant impact gsk operations refinement ehs reporting implementation new reporting system annual communication progress geographical spread inclusion complete ehs data seen improvements data reporting demonstrate uphold ten principles commercial operations business many areas business data interviews senior ehs staff understand review supporting guidance procedures responsible business supplement feedback counts gsks objectives approach data fully meet requirements new system used sites improve management welcome feedback collation management completion revised approach ehs programmes responsible business performance detection anomalies logging change continue working sites improve reporting please contact us consolidated ehs datasets data submission including providing comments csrcontactgskcom also request explanation trends complete receive regular updates progress timely fashion london february